ArticleFrontiers in cell and developmental biology2026
Multifaceted mechanistic exploration of
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthma, a chronic inflammatory respiratory disease with significant global health burden, faces limitations in current therapies, necessitating novel therapeutic strategies. The plant Aim: To investigate the anti-asthmatic mechanisms of GWM by identifying compounds and elucidating key molecular targets involved in immune cell regulation through integrated computational and experimental approaches. Methods: We employed UPLC-QE-Orbitrap-MS to identify active compounds. Network pharmacology and machine learning analyses were conducted to identify key hub genes, followed by validation through Mendelian randomization analysis, molecular docking, and animal models. Immune infiltration and single-cell RNA sequencing analyses using publicly available Gene Expression Omnibus (GEO) datasets, combined with mediation Mendelian randomization (MR), were performed to elucidate the underlying cellular mechanisms. Results: A total of 43 compounds were identified in GWM. Network pharmacology and machine learning prioritized NOTCH2, HDAC2, and MAPK1 as hub targets, validated using MR and molecular docking. Subsequent Conclusion: This study provides novel evidence for the potential therapeutic activity of GWM in asthma. By targeting key hub genes such as NOTCH2, HDAC2, and MAPK1, GWM may modulate immune cell activity, thereby contributing to its anti-asthmatic effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.